Art. -Nr.: HY-N0021

Verbascoside

(Synonyms: Acteoside; Kusaginin; TJC160)

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

Verbascoside is isolated from Acanthus mollis, acts as an ATP-competitive inhibitor of PKC, with an IC₅₀ of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 61276-17-3
Formel: C₂₉H₃₆O₁₅
Molecular Weight:624.59

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Verbascoside Chemical Structure

CAS. Nr.: 61276-17-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

PKC

25 μM (IC₅₀)

Alle PKC Isoform-spezifische Produkte anzeigen :

Alle HSV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.81 μM Compound: 2	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
Erythrocyte	IC₅₀	28 μM Compound: 6	Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs	[PMID: 12828473]
HCT-15	IC₅₀	2.73 μM Compound: 2	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
HEp-2	EC₅₀	0.26 μg/mL Compound: 1, verbascoside	Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	EC₅₀	0.8 μg/mL Compound: 1, verbascoside	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	76.9 μg/mL Compound: 1, verbascoside	Cytotoxicity against RSV long infected human Hep2 cells after 3 days Cytotoxicity against RSV long infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	9.7 μg/mL Compound: 1, verbascoside	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	IC₅₀	108 μg/mL Compound: 1, verbascoside	Cytotoxicity against human Hep2 cells administered 3 hrs postinfection Cytotoxicity against human Hep2 cells administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	44 μg/mL Compound: 1, verbascoside	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	71 μg/mL Compound: 1, verbascoside	Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Cytotoxicity against HSV2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	0.8 μg/mL Compound: 4	Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 9784173]
HEp-2	IC₅₀	76.9 μg/mL Compound: 4	Cytotoxicity against human Hep2 cells Cytotoxicity against human Hep2 cells	[PMID: 9784173]
Hepatocyte	IC₅₀	4.6 μM Compound: 5	Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
J774.A1	EC₅₀	4.9 x 10^-4 M Compound: 2	Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay	[PMID: 16309308]
L1210	IC₅₀	13 μM Compound: 1	Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 1812212]
L929	IC₅₀	17.8 μg/mL Compound: 5	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
P388	ED₅₀	2.6 μg/mL Compound: 1	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 2380718]
Peritoneal macrophage	IC₅₀	>100 μM Compound: 5	Inhibition of LPS-induced nitric oxide production in ddY mouse peritoneal macrophages Inhibition of LPS-induced nitric oxide production in ddY mouse peritoneal macrophages	[PMID: 20159656]
Peritoneal macrophage	IC₅₀	>100 μM Compound: 5	Inhibition of LPS-induced TNFalpha production in ddY mouse peritoneal macrophages Inhibition of LPS-induced TNFalpha production in ddY mouse peritoneal macrophages	[PMID: 20159656]
SK-MEL-2	IC₅₀	8.52 μM Compound: 2	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
SK-OV-3	IC₅₀	7.61 μM Compound: 2	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]

In Vitro

Verbascoside acts as an ATP-competitive inhibitor of PKC, with an IC₅₀ of 25 μM. Verbascoside shows K_is of 22 and 28 μM with respect to ATP and histone, respectively. Verbascoside has potent antitumor activity against L-1210 cells, with an IC₅₀ of 13 μM^[1]. Verbascoside (5, 10 μM) suppresses 2,4-dinitrochlorobenzene (DNCB)-induced T cell costimulatory factors CD86 and CD54, proinflammatory cytokines, and NFκB pathway activation in THP-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Verbascoside (1%) reduces the overall scratching behavior incidence as well as the severity of the skin lesions in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) mice model. Verbascoside also blocks DNCB-induced expression of proinflammatory cytokine TNF-α, IL-6, and IL-4 mRNA in skin lesions^[2]. Verbascoside (50, 100 mg/kg, i.p.) does not modify chronic constriction injury (CCI)-induced cold allodynia. Verbascoside (200 mg/kg, i.p.) decreases hyper-sensitivity to cold stimulus, acetone, on day 3 in rats. Verbascoside also significantly reduces behavioral changes associated with neuropathy. Moreover, Verbascoside decreases Bax and increases Bcl-2 on day 3^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 61276-17-3
Appearance Solid
Molecular Weight 624.59
Formel C₂₉H₃₆O₁₅
Color White to yellow
SMILES

O[C@@H]([C@H](OCCC1=CC(O)=C(O)C=C1)O2)[C@H]([C@@H]([C@H]2CO)OC(/C=C/C3=CC(O)=C(O)C=C3)=O)O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O
Synonyms

Acteoside; Kusaginin; TJC160
Structure Classification
- Phenols
- Polyphenols
Initial Source
- Plants
- Acanthaceae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (15)

All In Vivo Efficacy StudyHistological Imaging/StainingIFWBCell Proliferation/Viability AssayIP

Sort by:

Journal Impact Factor

Cell

Whitefly hijacks a plant detoxification gene that neutralizes plant toxins. [Abstract]

2021 Apr 1;184(7):1693-1705.e17. PMID: 33770502
Dev Cell

STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma. [Abstract]

2025 Jun 23;60(12):1751-1767.e9. PMID: 39933531

Verbascoside purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Jun 23;60(12):1751-1767.e9. [Abstract]

Verbascoside (VB; 10 μM; 24 h) did not interfere with CHI3L1-STAT3 interaction.
J Ethnopharmacol

Radix Rehmanniae Praeparata promoted zebrafish fin regeneration through aryl hydrocarbon receptor-dependent autophagy. [Abstract]

2024 May 6:331:118272. PMID: 38710459

Verbascoside purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 May 6:331:118272. [Abstract]

Bar charts showing the length of the regenerating fin of zebrafish exposure to different concentrations of Verbascoside (40, 80, 100, 150 mg/mL) ingredients at 2 dpa.
Int J Mol Sci

Plantago major and Plantago lanceolata Exhibit Antioxidant and Borrelia burgdorferi Inhibiting Activities. [Abstract]

2024 Jun 28;25(13):7112. PMID: 39000214
Cell Cycle

Osteopontin-driven partial epithelial-mesenchymal transition governs the development of middle ear cholesteatoma. [Abstract]

2024 Mar;23(5):537-554. PMID: 38662954

Verbascoside purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Mar;23(5):537-554. [Abstract]

Verbascoside (CD44 inhibitor; 1.87 μg/ear; 0.2 mL administered into the middle ears) in Six weeks old male Sprague-Dawley (SD) rats could remarkably ameliorate these symptoms could ameliorate the development of middle ear cholesteatoma.
FOOD BIOPROD PROCESS

2023 Feb 11.
Neurotox Res

Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]

2026 Mar 19;44(2):12. PMID: 41854817
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Arch Physiol Biochem

Verbascoside attenuates angiotensin-induced hypertension by inhibiting endoplasmic reticulum stress via the Nur77/GFPT2/CHOP pathway. [Abstract]

2025 Nov 24:1-19. PMID: 41284022
Pancreatology

Expression of versican isoforms V0/V1 by pancreatic cancer associated fibroblasts increases fibroblast proliferation. [Abstract]

2024 Aug;24(5):719-731. PMID: 38719756
Arch Physiol Biochem

Actoeside mitigated the renal proximal tubule cells damage triggered by high glucose through miR-766/VCAM1/NF-κB signalling pathway. [Abstract]

2023 Dec;129(6):1177-1186. PMID: 34338087
Cell Biochem Biophys

Acteoside Presents Protective Effects on Cerebral Ischemia/reperfusion Injury Through Targeting CCL2, CXCL10, and ICAM1. [Abstract]

2021 Jun;79(2):301-310. PMID: 33439460
SSRN

2023 Oct 31.
Acta medica mediterr

2023 Feb 28.

Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.

Verbascoside (75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice at a dose of 150 mg/kg/d (db-150VB) significantly lowered the fasting blood glucose (FBG) level and albumin-to-creatinine ratio (ACR) compared to db/db mice.

Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.

Verbascoside (VB; 75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice at a dose of 150 mg/kg/d (db-150VB) alleviated kidney pathologic damage, which was characterized by mesangial matrix expansion and glomerulosclerosis compared to diabetic mice.

Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.

Verbascoside (VB; 75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice restored the decreased expression of nephrin and podocin.

Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.

Verbascoside (VB; 75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice effectively reduced the IL-6, CXCL10, and MCP-1 protein expression in renal tissues, especially in the 150 mg/kg/d dose group.

Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.

The cytotoxic effect of verbascoside (25, 50, 75, 100, 200, 300 and 400 μM) on MPC5 for 24 h determined by Cell Counting Kit-8 assay.
Patent

US20210085739A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (160.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (160.11 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6011 mL

8.0053 mL

16.0105 mL

5 mM

0.3202 mL

1.6011 mL

3.2021 mL

10 mM

0.1601 mL

0.8005 mL

1.6011 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Cell Assay^[1]

The lymphocytic mouse leukemia L1210 cells (ATCC, CCL 219) are plated sparsely at 10⁴ cells per well in 24-well cluster plates in Dulbecco’s modified Eagle medium containing 10% fetal calf serum, 4 mM glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin sulfate, and Verbascoside (solubilized in DMSO). After a 2-day incubation period at 37°C in a humidified atmosphere (5% CO₂ in air), growth is monitored by counting cell numbers in a Coulter-counter. IC₅₀ values are calculated on the basis of the linear regression lines established for each compound tested^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Rats^[2]
To induce atopic dermatitis (AD)-like symptoms, 2,4-dinitrochlorobenzene (DNCB) is used. Briefly, the dorsal hair of the mice is removed using an electronic clipper 2 days before DNCB treatment. An application of 200 µL of 1% DNCB (in acetone:olive oil = 4:1) is made to the shaved dorsal skin for sensitization. The repeated challenge is performed on the same site with 0.2% DNCB once every 3 days for about 2 weeks. The mice are divided into 4 groups (n = 6 per group): (1) vehicle-treated controls, (2) DNCB-treated only, (3) 1% Verbascoside (in acetone:olive oil 4:1)-treated only, and (4) DNCB + 1% Verbascoside-treated group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Herbert JM, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. J Nat Prod. 1991 Nov-Dec;54(6):1595-600. [Content Brief]

[2]. Li Y, et al. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. Int Arch Allergy Immunol. 2018;175(4):220-230. [Content Brief]

[3]. Amin B, et al. The Effect of Verbascoside in Neuropathic Pain Induced by Chronic Constriction Injury in Rats. Phytother Res. 2016 Jan;30(1):128-35. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.6011 mL	8.0053 mL	16.0105 mL	40.0263 mL
	5 mM	0.3202 mL	1.6011 mL	3.2021 mL	8.0053 mL
	10 mM	0.1601 mL	0.8005 mL	1.6011 mL	4.0026 mL
	15 mM	0.1067 mL	0.5337 mL	1.0674 mL	2.6684 mL
	20 mM	0.0801 mL	0.4003 mL	0.8005 mL	2.0013 mL
	25 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6011 mL
	30 mM	0.0534 mL	0.2668 mL	0.5337 mL	1.3342 mL
	40 mM	0.0400 mL	0.2001 mL	0.4003 mL	1.0007 mL
	50 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8005 mL
	60 mM	0.0267 mL	0.1334 mL	0.2668 mL	0.6671 mL
	80 mM	0.0200 mL	0.1001 mL	0.2001 mL	0.5003 mL
	100 mM	0.0160 mL	0.0801 mL	0.1601 mL	0.4003 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Verbascoside

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Verbascoside

Anti-Infection Compound Library

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Phenols Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Aging Natural Product Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Verbascoside

Alle PKC Isoform-spezifische Produkte anzeigen

Alle HSV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Verbascoside Related Classifications

HY-N0021 Related Classifications